Toujeo patent?

When will the Toujeo patent expire?
The main formulation patent for Toujeo insulin‑glargine (U‑300) was filed in the early 2000s and has a 20‑year term from filing. The current U‑300 patent is set to expire in 2029, opening the possibility for biosimilar competition thereafter. [1]

Who holds the Toujeo patent rights?
Sanofi Health holds the patent portfolio for Toujeo, including the concentration, delivery device, and manufacturing process patents. The company has also secured secondary patents that extend market exclusivity for specific use cases. [1]

Can biosimilar or generic versions enter the market before 2029?
Because the core formulation patent is still active, generic manufacturers cannot legally produce a U‑300 insulin until the 2029 expiration. Some biosimilar candidates are in development, but they must wait until the patent lapses or negotiate a licensing agreement with Sanofi. [1]

How does Toujeo compare to Lantus (U‑100) in terms of patent protection?
Lantus, another insulin‑glargine product, is protected by separate patents that also expire around 2029. Toujeo’s higher concentration offers dosing convenience, but both products share overlapping patent coverage, limiting biosimilar entry until similar expiration dates. [1]

What legal challenges have surrounded Toujeo’s patents?
There have been a few patent infringement suits, primarily involving generic manufacturers attempting to launch U‑300 products before the expiration. Sanofi has defended its patents vigorously, and the courts have upheld the validity of the core U‑300 claims. [1]

When did Sanofi launch Toujeo and how has the market responded?
Toujeo was introduced in 2013 as a 300 U/mL insulin‑glargine formulation. It quickly gained market share among patients needing tighter glucose control, and the higher concentration has helped reduce injection volume for some users. The product’s patent protection has sustained its premium pricing throughout its lifespan. [1]

Will the expiration of Toujeo’s patent affect pricing?
Typically, once the patent expires, generic manufacturers can offer lower‑priced alternatives, which tends to reduce overall market prices. However, the presence of secondary patents and potential regulatory hurdles may delay a significant price drop. [1]

Can Sanofi or other companies extend exclusivity through new patents?
Sanofi has filed secondary patents on formulation tweaks and delivery devices that provide additional exclusivity layers. These patents could extend effective market protection beyond the core 2029 expiration, at least for certain product aspects. [1]

What should patients and prescribers expect post‑patent?
After 2029, prescribers may see biosimilar or generic Toujeo candidates enter formularies, offering cost savings. Patients may need to switch to alternative dosing regimens if a new product uses a different concentration or delivery mechanism. Close monitoring of insurance coverage and regulatory approvals will be important. [1]

---

Sources

1. https://www.drugpatentwatch.com/insulin-toujeo